Acute Myeloid Leukemia: The Challenge of Unfavorable Cytogenetics

August 3, 2012

Prognostic factors in acute myeloid leukemia (AML) may be subdivided into those related to patient characteristics and general health condition, and those related to characteristics of the tumor.

Disease Categorization

Prognostic factors in acute myeloid leukemia (AML) may be subdivided into those related to patient characteristics and general health condition, and those related to characteristics of the tumor.[1] Among the AML-related factors, the karyotype of the leukemic cells is the strongest independent prognostic indicator for response to therapy and for survival, and allows one to stratify patients into three cytogenetic risk groups: favorable, intermediate, and unfavorable.[1-4] The article by Drs. Orozco and Appelbaum gives an informative and systematic overview of biologic characteristics and treatment options for AML with unfavorable cytogenetics, focusing in particular on AML with complex and monosomal karyotypes.

While biologically different, all types of AML with unfavorable cytogenetic findings have a relatively poor outcome with currently available treatments.[1] However, two overlapping subgroups within the unfavorable risk category, AML with complex cytogenetics and AML with monosomal karyotype (MK), pose additional challenges.[5,6] The incidence of these subtypes increases with age, so that they are frequently encountered in older patients who more often have comorbidities and poor performance status, and thus are not candidates for intensive remission induction therapy and hematopoietic stem cell transplantation (HSCT).[7] Additionally, for reasons that still await biologic and molecular explanation, MK-AML appears associated with a particularly poor outcome.[8]

Drs. Orozco and Appelbaum offer a helpful overview of cytogenetic risk classification schemes developed over a period of almost 2 decades by large collaborative groups: the Southwest Oncology Group (SWOG), the Medical Research Council (MRC), and Cancer and Leukemia Group B (CALGB). Differences in classification schemes are relatively minor, and can be explained by the different patient populations enrolled in the SWOG, MRC, and CALGB trials, as well as by differing treatments. In addition, CALGB applies separate classification schemes depending on whether the outcome is measured by complete response rate (CR), relapse risk (RR) after CR, or overall survival (OS), to reflect the fact that abnormalities predicting, for example, resistance to induction therapy may differ from the ones predicting high risk of relapse. Importantly, all three classification schemes distinguish the three major prognostic groups (favorable, intermediate, and unfavorable) with good concordance regarding the cytogenetic abnormalities that predict favorable [t(8;21), inv(16)] as well as unfavorable outcome [complex karyotype, abn(3q)].[2-4,9]

More recently, the characterization of a number of molecular markers has allowed further refinement of risk stratification in AML.[10] At this time, however, molecular profiling does not appear to offer additional prognostic information for patients with unfavorable risk cytogenetics. Systematic evaluation for an increasing number of nonrandom mutations in AML has allowed better stratification of AMLs with normal cytogenetics (CN-AML), which represent a large proportion (almost 50%) of newly diagnosed cases.[11] The recently proposed European Leukemia Network (ELN) classification uses the presence of the FLT3-ITD mutation, as well as CEBPA and NPM1 mutation status, to stratify AML with intermediate-risk cytogenetics, including CN-AML.[12] This classification uses the molecular markers to subdivide the intermediate-risk AML into a more favorable Intermediate-I and a less favorable Intermediate-II category. The prognostic value of this risk classification has been tested on two large cohorts of patients (the AML96 trial and CALGB patient cohorts), and the data suggest that this may be the best system for outcome prediction in AML available to date.[12,13] Undoubtedly, this genetic classification will evolve as new recurring mutations are discovered that influence the outcome of AML treatment.

In addition to implementation of molecular markers, the increased use of HSCT has an impact on risk stratification and outcomes in AML. It is important to remember that the current classification schemes are based on historical SWOG, CALGB, and MRC trials that used chemotherapy as the main treatment modality; it remains to be seen whether HSCT can overcome the adverse effects of some high- and intermediate-risk karyotypes.

Regarding the biology and molecular pathogenesis of unfavorable-risk AML, the association of a complex karyotype with poor prognosis comes as no surprise. In cancer cytogenetics, karyotype complexity has traditionally been considered as a sign of clonal evolution and high mutation load, particularly in the presence of multiple related abnormal clones. The high incidence of complex karyotypes in older patients, and in AML with myelodysplastic changes, AML evolving from myelodysplastic syndrome (MDS), and therapy-related AML, suggests that AML with complex karyotype results from the accumulation of large numbers of mutations as patients age, as they are exposed to mutagenic agents, or as hematopoiesis becomes increasingly more disordered in a MDS clone.[7,14]

It is more challenging to hypothesize about molecular mechanisms responsible for the progressive course in AML with isolated unfavorable cytogenetic abnormalities, such as t(6;9), which are often seen in younger patients, and in which cases a limited number of mutations appears sufficient to result in an aggressive and chemotherapy-resistant disease.[15]

Similarly puzzling is the recently described category of AML with MK, and its reportedly dismal prognosis.[6,8] The uniqueness of this category is controversial, because of its substantial overlap with complex-karyotype AML and AML with monosomy 7, both of which are well recognized unfavorable categories. However, several studies support MK as a predictor of a particularly poor outcome, independent of complex karyotype. A recent SWOG analysis found that the 4-year survival for patients with complex cytogenetics but without an MK was 13%, but for those with an MK it was only 3%.[16] Clearly, both of these outcomes are quite poor.

Therapy: Focus on Allogeneic HSCT

Clinical trials that tested various modifications of the standard “cytarabine plus an anthracycline” induction regimen, such as increasing the anthracycline dose, or the use of alternative anthracyclines, high-dose cytarabine, or additional agents given with conventional 7+3 chemotherapy, have demonstrated little or no advantage for AML patients with unfavorable cytogenetics.[17-21] In contrast, improved outcomes following allogeneic HSCT have been clearly documented for younger adults with unfavorable cytogenetics, and more recently, for patients with MK-AML.[22-26] HSCT is recommended for young patients with poor-risk AML, and the question has shifted to how to make it more feasible and more effective for a higher proportion of these patients. Data from single centers and transplant registries show that outcomes after transplants from HLA-matched unrelated donors are similar to those from matched siblings.[27,28] In addition, although transplant-related mortality is higher with use of cord-blood transplants or alternative donors, relapse rates among transplanted patients are decreased compared with those given chemotherapy alone, leading to better long-term survival.[29] Therefore, it may soon be possible to offer transplantation to almost all young patients with high-risk AML who achieve a CR. Additionally, non-myeloablative and reduced-intensity conditioning regimens are increasingly making HSCT an option for older patients and those with comorbid conditions, although further studies are necessary to demonstrate a survival advantage of HSCT over chemotherapy for fit but older patients with high-risk AML.[30,31]

Many older patients with complex-karyotype, MK, and other high-risk–karyotype AMLs, however, are not candidates for either HSCT or intensive chemotherapy. Their treatment options are quite limited and unproven. Clinical trials of novel therapeutics should be recommended. Palliative treatment with clofarabine (Clolar), azacitidine (Vidaza), or decitabine (Dacogen) can achieve some disease control.[32-34]

Finally, one must not forget that even with all available forms of therapy, including HSCT, the outcomes for unfavorable-risk AML remain generally poor. The obvious question becomes that of what the prospects are for developing completely novel therapeutic approaches, at least for some categories of unfavorable-cytogenetics AML. As nicely discussed in this review article, for subsets of high-risk AML, such as t(6;9) AML, in which a limited number of mutations may be driving the disease, it may be feasible to develop specific inhibitors of the key molecular pathways involved in leukemogenesis and the survival of leukemia stem cells.[15] However, development of effective small-molecule inhibitors will be a challenge for AML with more complex karyotypes and MK-AML, which appear to be associated with higher mutation burdens, frequently carry TP53 mutations, express anti-apoptotic proteins, and commonly display multidrug resistance. Immune-based therapies merit investigation, as they might offer some benefit to patients in these most challenging categories of AML.[35]

Financial Disclosure: The authors have no significant financial interest or other relationship with the manufacturers of any products or providers of any service mentioned in this article.

This work was supported in part by grants CA40046 and CA14599 from the National Cancer Institute of the National Institutes of Health.




1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-74.

2. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075-83.

3. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325-36.

4. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354-65.

5. Chen CC, Yang CF, Lee KD, et al. Complex karyotypes confer a poor survival in adult acute myeloid leukemia with unfavorable cytogenetic abnormalities. Cancer Genet Cytogenet. 2007;174:138-46.

6. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791-7.

7. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-5.

8. Kayser S, Zucknick M, Dohner K, et al. Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies. Blood. 2012;119:551-8.

9. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-20.

10. Marcucci G, Haferlach T, Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29:475-86.

11. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115-36.

12. Rollig C, Bornhauser M, Thiede C, et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J Clin Oncol. 2011;29:2758-65.

13. Mrózek K, Marcucci G, Maharry K, et al. Prognostic utility of the European LeukemiaNet (ELN) genetic-risk classification in adults with de novo acute myeloid leukemia (AML): a study of 1,550 patients (pts) (ASH Annual Meeting Abstracts). Blood. 2011;118:abstr 414.

14. Appelbaum FR, Gundacker HM. Age and the nature of acute myeloid leukemia. Ann Hematol. 2004;83(Suppl 1):S106-7.

15. Slovak ML, Gundacker H, Bloomfield CD, et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ’poor prognosis’ myeloid malignancies. Leukemia. 2006;20:1295-7.

16. Medeiros BC, Othus M, Fang M, et al. Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood. 2010;116:2224-8.

17. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361:1249-59.

18. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992;10:1103-11.

19. Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-9.

20. Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027-36.

21. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29:369-77.

22. Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer. 2005;103:1652-8.

23. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009;301:2349-61.

24. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109:3658-66.

25. Fang M, Storer B, Estey E, et al. Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation. Blood. 2011;118:1490-4.

26. Cornelissen JJ, Breems D, van Putten WL, et al. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012;30:2140-6.

27. Walter RB, Pagel JM, Gooley TA, et al. Comparison of matched unrelated and matched related donor myeloablative hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission. Leukemia. 2010;24:1276-82.

28. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood. 2010;116:1839-48.

29. Brunstein CG, Gutman JA, Weisdorf DJ, et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood. 2010;116:4693-9.

30. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. 2010;28:2859-67.

31. Kurosawa S, Yamaguchi T, Uchida N, et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-M3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant. 2011;17:401-11.

32. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. 2010;28:2389-95.

33. Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma. 2012;53:110-7.

34. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. 2010;28:556-61.

35. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725-33.